Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

an "enriched" enrollment, double-blind, placebo-controlled, randomized withdrawal study measuring the efficacy and safety of BEMA Buprenorphine in patients with moderate to severe chronic pain.  Patients meeting the designated study criteria undergo titration with BEMA Buprenorphine to a dose that is both effective and well-tolerated.  Those patients who identify an effective and well tolerated dose are then randomized to either continue their BEMA Buprenorphine dose or begin use of a placebo (BEMA film with no active drug) for twelve weeks.  The primary efficacy measure is the mean change in pain intensity from the time patients are randomized (to BEMA Buprenorphine or placebo) through to the end of the twelve week study period.  The study design described has been utilized for a number of the opioid analgesics approved by the FDA in recent years.  The study design includes an interim analysis to confirm the number of patients needed for adequate statistical power.  This interim analysis is part of the study design agreed upon with FDA and is included solely to provide assurance that the sample size is adequate to detect the effect difference between the active and placebo treatments. 

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada,
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 Elekta, ... on cancer survivorship on September 10, 6:30-8:30 p.m., at Elekta,s ... Elekta,s Ultimate Ride to Survivorship " will feature Professional BMX ... treatment of a brain tumor with Leksell Gamma Knife®, Elekta,s ... 48,070 new cancer cases will be diagnosed in ...
(Date:9/2/2015)... Mass. , Sept. 2, 2015 Boston Scientific ... the 2015 Morgan Stanley Global Healthcare Conference on September 17, ... Mike Mahoney , chief executive officer, and Dan ... participate in a 30-minute question and answer session regarding the ... ET. A live webcast of the question and ...
(Date:9/2/2015)... 2015  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... has entered into a definitive agreement under which Valeant ... (NASDAQ: SURG ) for $6.50 per share in ... stockholders will receive additional cash payments of up to ... following the closing.  The transaction is expected to close ...
Breaking Medicine Technology:Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 2Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 3Boston Scientific To Participate In 2015 Morgan Stanley Global Healthcare Conference 2Valeant Pharmaceuticals To Acquire Synergetics USA 2Valeant Pharmaceuticals To Acquire Synergetics USA 3Valeant Pharmaceuticals To Acquire Synergetics USA 4Valeant Pharmaceuticals To Acquire Synergetics USA 5
(Date:9/2/2015)... ... 02, 2015 , ... The Hydration Room, Orange County’s first ... second location this week at 31542 S. Coast Hwy, Suite #4, Laguna Beach, ... for patients to relax while receiving safe and effective therapies. Also offering complimentary ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... companies, has completed a recapitalization with new investment partners Beecken Petty O’Keefe ... Group each offer extensive expertise and connections within the healthcare industry, which ...
(Date:9/2/2015)... ... September 02, 2015 , ... The ... two day international investment and business conference will be hosted at five star ... China. The full-weekend networking conference will feature leading EB-5 industry professionals and Chinese ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... patented products, announces Hand Free Pocket Cop, a safety invention that protects people ... US is worth $31 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:9/2/2015)... ... September 02, 2015 , ... EDAC Systems, Inc., a leading ... and services to both government and commercial clients, today announced the release of ... IBM’s Datacap document capture platform. EDAC PurePAGE processes and enhances the images ...
Breaking Medicine News(10 mins):Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3
... for ambulatory care ... ... Cardiac Science,Corporation, (Nasdaq: CSCX ), a leading provider of ... of its HeartCentrix(R) ECG informatics software with Greenway,Medical Technology,s PrimeSuite(R) ...
... to US$5.5 million -, BELLEVILLE, ON, Dec. ... a research-based, technology-driven Canadian,biopharmaceutical company, today announced that ... its long-term convertible debt with Laurus Master,Funds., ... will now have a maximum,borrowing limit of US$5.5 ...
... Upon an ex parte motion,by the Service ... order (TRO) was issued late on Thursday, December ... County, Michigan,enjoining the Michigan Department of Community Health, ... Carlyle Group from taking certain actions related to,completing ...
... 20 Percent of Cost for New Hospital, SAN ... has reached its $50 million Capital Campaign,goal, the largest ... recent gift of $500,000 from the Stephen and Mary ... http://www.newscom.com/cgi-bin/prnh/20071220/DC10448 ), "It,s only fitting that ...
... For ... Breast Cancer Research., NEWPORT NEWS, Va., Dec. 20 ... Inc. of San Diego,California have settled their lawsuit over Dilon,s ... Dilon in the U.S.,District Court for the Southern District of ...
... gives DRAXIMAGE strong competitive position ... MONTREAL, Dec. 20 /PRNewswire-FirstCall/ - DRAXIMAGE, the,radiopharmaceutical ... (NASDAQ:,DRAX), has appointed GE Healthcare, an industry ... of DRAXIMAGE(R) Sestamibi in the United,States. DRAXIMAGE(R) ...
Cached Medicine News:Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 3Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 4Health News:Bioniche Amends Terms of Convertible Debt with Laurus Master Funds 2Health News:Manor Care To Vigorously Contest TRO 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 2Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 3Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 4Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 5Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 6Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 7
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: